These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

307 related articles for article (PubMed ID: 15144573)

  • 21. Recombinant human interferon gamma in the treatment of cervical intraepithelial neoplasia (CIN) associated with human papillomavirus (HPV) infection.
    Sikorski M; Zrubek H
    Eur J Gynaecol Oncol; 2003; 24(2):147-50. PubMed ID: 12701965
    [TBL] [Abstract][Full Text] [Related]  

  • 22. High-risk HPV testing in women with borderline and mild dyskaryosis: long-term follow-up data and clinical relevance.
    Denise Zielinski G; Snijders PJ; Rozendaal L; Voorhorst FJ; Runsink AP; de Schipper FA; Meijer CJ
    J Pathol; 2001 Oct; 195(3):300-6. PubMed ID: 11673826
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Adeno-associated virus infection and cervical neoplasia: is there a protective role against human papillomavirus-related carcinogenesis?
    Agorastos T; Chrisafi S; Lambropoulos AF; Mikos T; Constandinides TC; Schlehofer JR; Schlehofer B; Kotsis A; Bontis JN
    Eur J Cancer Prev; 2008 Aug; 17(4):364-8. PubMed ID: 18562963
    [TBL] [Abstract][Full Text] [Related]  

  • 24. The impact of human papillomavirus type on colposcopy performance in women offered HPV immunisation in a catch-up vaccine programme: a two-centre observational study.
    Munro A; Gillespie C; Cotton S; Busby-Earle C; Kavanagh K; Cuschieri K; Cubie H; Robertson C; Smart L; Pollock K; Moore C; Palmer T; Cruickshank ME
    BJOG; 2017 Aug; 124(9):1394-1401. PubMed ID: 28102931
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Efficacy of a bivalent L1 virus-like particle vaccine in prevention of infection with human papillomavirus types 16 and 18 in young women: a randomised controlled trial.
    Harper DM; Franco EL; Wheeler C; Ferris DG; Jenkins D; Schuind A; Zahaf T; Innis B; Naud P; De Carvalho NS; Roteli-Martins CM; Teixeira J; Blatter MM; Korn AP; Quint W; Dubin G;
    Lancet; 2004 Nov 13-19; 364(9447):1757-65. PubMed ID: 15541448
    [TBL] [Abstract][Full Text] [Related]  

  • 26. High-risk human papilloma virus management in pregnancy with cervical intraepithelial neoplasia during pregnancy and postpartum in China.
    He Y; Wu YM; Zhao Q; Wang T; Song F; Zhu L
    J Obstet Gynaecol Res; 2014 Feb; 40(2):538-44. PubMed ID: 24125014
    [TBL] [Abstract][Full Text] [Related]  

  • 27. [Wait-and-see policy versus loop excision after two consecutive Pap-2 cervical smears: over time less surgery and an equivalent outcome; no substantial contribution to be expected from the detection of high risk human papillomavirus].
    Bekkers RL; Hanselaar AG; Melchers WJ; van Schaik JH; Boonstra H; Massuger LF
    Ned Tijdschr Geneeskd; 2003 Feb; 147(7):302-6. PubMed ID: 12622008
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Screening properties of human papillomavirus testing for predicting cervical intraepithelial neoplasia in atypical squamous cells of undetermined significance and low-grade squamous intraepithelial lesion smears: a prospective study.
    Dane C; Batmaz G; Dane B; Cetin A
    Ann Diagn Pathol; 2009 Apr; 13(2):73-7. PubMed ID: 19302953
    [TBL] [Abstract][Full Text] [Related]  

  • 29. A phase I trial of a human papillomavirus (HPV) peptide vaccine for women with high-grade cervical and vulvar intraepithelial neoplasia who are HPV 16 positive.
    Muderspach L; Wilczynski S; Roman L; Bade L; Felix J; Small LA; Kast WM; Fascio G; Marty V; Weber J
    Clin Cancer Res; 2000 Sep; 6(9):3406-16. PubMed ID: 10999722
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Prediction of recurrence after treatment for high-grade cervical intraepithelial neoplasia: the role of human papillomavirus testing and age at conisation.
    Verguts J; Bronselaer B; Donders G; Arbyn M; Van Eldere J; Drijkoningen M; Poppe W
    BJOG; 2006 Nov; 113(11):1303-7. PubMed ID: 16978225
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Adjuvant Human Papillomavirus Vaccine to Reduce Recurrent Cervical Dysplasia in Unvaccinated Women: A Systematic Review and Meta-analysis.
    Lichter K; Krause D; Xu J; Tsai SHL; Hage C; Weston E; Eke A; Levinson K
    Obstet Gynecol; 2020 May; 135(5):1070-1083. PubMed ID: 32282601
    [TBL] [Abstract][Full Text] [Related]  

  • 32. [Association between high-risk human papillomavirus DNA load and different histological grades of cervical neoplasia].
    Zhao FH; Hu SY; Wang SM; Chen F; Zhang X; Zhang WH; Pan QJ; Qiao YL
    Zhonghua Yu Fang Yi Xue Za Zhi; 2009 Jul; 43(7):565-70. PubMed ID: 19954065
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Description of a seven-year prospective study of human papillomavirus infection and cervical neoplasia among 10000 women in Guanacaste, Costa Rica,
    Bratti MC; Rodríguez AC; Schiffman M; Hildesheim A; Morales J; Alfaro M; Guillén D; Hutchinson M; Sherman ME; Eklund C; Schussler J; Buckland J; Morera LA; Cárdenas F; Barrantes M; Pérez E; Cox TJ; Burk RD; Herrero R
    Rev Panam Salud Publica; 2004 Feb; 15(2):75-89. PubMed ID: 15030652
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Simultaneous effects of aneuploidy and oncogenic human papillomavirus on histological grade of cervical intraepithelial neoplasia.
    Monsonego J; Valensi P; Zerat L; Clavel C; Birembaut P
    Br J Obstet Gynaecol; 1997 Jun; 104(6):723-7. PubMed ID: 9197877
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Combined human papillomavirus DNA and human papillomavirus-like particle serologic assay to identify women at risk for high-grade cervical intraepithelial neoplasia.
    Einstein MH; Studentsov YY; Ho GY; Fazzari M; Marks M; Kadish AS; Goldberg GL; Runowicz CD; Burk RD
    Int J Cancer; 2007 Jan; 120(1):55-9. PubMed ID: 17036320
    [TBL] [Abstract][Full Text] [Related]  

  • 36. [Human papillomavirus infection and cervical intraepithelial neoplasia].
    Sevcík L; Koliba P; Konderla M; Gráf P; Hlavacka J
    Ceska Gynekol; 2003 Jul; 68(4):237-43. PubMed ID: 14515645
    [TBL] [Abstract][Full Text] [Related]  

  • 37. The clinical effectiveness and cost-effectiveness of primary human papillomavirus cervical screening in England: extended follow-up of the ARTISTIC randomised trial cohort through three screening rounds.
    C Kitchener H; Canfell K; Gilham C; Sargent A; Roberts C; Desai M; Peto J
    Health Technol Assess; 2014 Apr; 18(23):1-196. PubMed ID: 24762804
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Candidate HPV genotypes not included in the 9-valent vaccine for prevention of CIN 2-3.
    Gonzalez-Bosquet E; Gibert M; Serra M; Hernandez-Saborit A; Gonzalez-Fernandez A
    Int J Gynecol Cancer; 2020 Jul; 30(7):954-958. PubMed ID: 32467333
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Cervical infections by multiple human papillomavirus (HPV) genotypes: Prevalence and impact on the risk of precancerous epithelial lesions.
    Bello BD; Spinillo A; Alberizzi P; Cesari S; Gardella B; D'Ambrosio G; Roccio M; Silini EM
    J Med Virol; 2009 Apr; 81(4):703-12. PubMed ID: 19235847
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Safety, efficacy, and immunogenicity of VGX-3100, a therapeutic synthetic DNA vaccine targeting human papillomavirus 16 and 18 E6 and E7 proteins for cervical intraepithelial neoplasia 2/3: a randomised, double-blind, placebo-controlled phase 2b trial.
    Trimble CL; Morrow MP; Kraynyak KA; Shen X; Dallas M; Yan J; Edwards L; Parker RL; Denny L; Giffear M; Brown AS; Marcozzi-Pierce K; Shah D; Slager AM; Sylvester AJ; Khan A; Broderick KE; Juba RJ; Herring TA; Boyer J; Lee J; Sardesai NY; Weiner DB; Bagarazzi ML
    Lancet; 2015 Nov; 386(10008):2078-2088. PubMed ID: 26386540
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 16.